Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg ...

This new approach, based on natural selection, dramatically improves the reliability of large language models for practical ...

The order, signed in October 2023, required companies building powerful AI systems to share their safety test results with the federal government and come up with ways to limit their models’ biases ...

Google's DeepMind leads the market with Gemini, TPU chips, and cloud growth, making its valuations compelling compared to its ...

The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.

Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups ...

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big ...

Jeff Dean, chief scientist of Google DeepMind, stated: The model's design leverages extended computation during inference to improve reasoning outcomes. And Logan Kilpatrick, AI Studio’s product ...

Demis Hassabis is the CEO of Google DeepMind. Demis thinks new agent type systems will be able to perform additional tree of ...

Tim Brooks left OpenAI last fall and moved to Google DeepMind. There, the AI expert is building a new team that will work on ...